Article Text

Download PDFPDF
Expression of programmed death-ligand 1 protein in pulmonary squamous cell carcinoma correlates with tumour necrosis but not with tumour differentiation
  1. Vladimír Tancoš1,
  2. Anna Farkašová2,
  3. Zuzana Kviatkovská2,
  4. Marián Grendár1,
  5. Alena Líšková1,
  6. Zdenko Huťka1,
  7. Lukáš Plank1,2
  1. 1Univerzita Komenského v Bratislave Jesseniova Lekárska Fakulta v Martine, Martin, Slovakia
  2. 2Martin's Biopsy Centre Ltd, Martin, Slovakia
  1. Correspondence to Professor Lukáš Plank, Univerzita Komenského v Bratislave Jesseniova Lekárska Fakulta v Martine, Martin 03659, Slovakia; lukas.plank{at}uniba.sk

Abstract

Aims Pulmonary squamous cell carcinoma (SqCC) represents the second most common non-small cell lung carcinoma type. The mechanisms which regulate programmed death ligand 1 (PD-L1) expression in this form of lung cancer are not fully elucidated yet.

Methods We immunohistochemically determined the level of PD-L1 expression using the Tumour Proportion Score system in surgical resections of 133 patients with pulmonary SqCC. The results from PD-L1 immunohistochemistry were analysed in relation to tumour differentiation and the presence of necrotic areas comprising at least 20% of the tumour mass.

Results No significant differences in terms of PD-L1 expression were found between SqCC subtypes as defined by the current WHO classification: better differentiated, keratinising tumours (12/24, 50.0 %) compared with less differentiated, non-keratinising and basaloid forms (62/109, 56.9 %) were PD-L1 positive in a comparable proportion of cases (p=0.1903). Contrary to that, SqCCs with the presence of necrosis (51/61, 83.6 %) had significantly more PD-L1-positive cases (p<0.001) compared with SqCCs without necrotic areas (23/72, 32.0 %)

Conclusions We demonstrated that PD-L1 expression in pulmonary SqCCs does not correlate with the traditionally defined degree of differentiation of these tumours. On the other hand, we found a significant association between the positive result of PD-L1 immunohistochemistry and tumour necrosis. Further investigation regarding the role of hypoxic pathways as presumable inducers of PD-L1 expression in pulmonary SqCCs might contribute to the understanding of this phenomenon.

  • lung neoplasms
  • biomarkers
  • tumour
  • pathology
  • molecular

Statistics from Altmetric.com

Footnotes

  • Handling editor Runjan Chetty.

  • Contributors All authors contributed to the conception and design of the final version of this manuscript and approved it. VT and LP designed the study, analysed and interpreted the results, and drafted the manuscript. MG performed the statistical analysis. AL drafted the work. AF, ZH and ZK collected and analysed the study material. LP supervised the study.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval The ethics committee of the Jessenius Faculty of Medicine in Martin has approved the study (EK 43/2019).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request. Deidentified patient data.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.